版本:
中国

BRIEF-Amunix says Versartis gets PMDA approval in Japan to initiate enrollment for phase 3 study of Somavaratan in pediatric patients

Oct 17 Versartis Inc

* Amunix says Versartis has been granted approval in Japan by PMDA to initiate enrollment for its phase 3 study of Somavaratan in pediatric patients

* Phase 3 trial of J14VR5 is expected to be completed in Q3 of 2017, with topline data expected in 2018. Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐